Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. PureTech Share Price
  4. PureTech Share Regulatory News
  5. Transaction in Own Shares

Pin to quick picksPureTech Regulatory News (PRTC)

PureTech Information

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
126.20    -0.40 (-0.32%)
Bid:
125.20
Ask:
125.80
Spread: 0.60 (0.479%)
Market Cap: £307.19m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Transaction in Own Shares

17 Nov 2023 07:00

RNS Number : 7572T
PureTech Health PLC
17 November 2023
 

17 November 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

16 November 2023

Number of ordinary shares purchased:

25,140

Highest price paid per share:

182.20p

Lowest price paid per share:

176.80p

Volume weighted average price paid per share:

179.00p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,310,999 ordinary shares in treasury and has 273,157,160 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 273,157,160 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

16/11/2023

11:47:14

189

182.2

AQXE

00378647894TRLO0.1.1

16/11/2023

11:47:14

44

182.2

XLON

00378647893TRLO0.1.1

16/11/2023

11:47:14

189

182.2

AQXE

00378647895TRLO0.1.1

16/11/2023

11:47:14

492

182.2

XLON

00378647896TRLO0.1.1

16/11/2023

11:47:14

96

182.2

TRQX

00378647898TRLO0.1.1

16/11/2023

11:47:14

96

182.2

TRQX

00378647897TRLO0.1.1

16/11/2023

11:49:35

536

182

CHIX

00378648134TRLO0.1.1

16/11/2023

11:49:43

36

181

BATE

00378648139TRLO0.1.1

16/11/2023

11:49:44

439

181

BATE

00378648140TRLO0.1.1

16/11/2023

11:55:04

536

180

XLON

00378648676TRLO0.1.1

16/11/2023

12:09:09

108

179

XLON

00378651730TRLO0.1.1

16/11/2023

12:09:09

428

179

XLON

00378651731TRLO0.1.1

16/11/2023

12:09:09

536

179

XLON

00378651732TRLO0.1.1

16/11/2023

12:19:03

765

178

XLON

00378653296TRLO0.1.1

16/11/2023

12:19:03

307

178

XLON

00378653295TRLO0.1.1

16/11/2023

12:24:44

56

178.2

XLON

00378653918TRLO0.1.1

16/11/2023

12:25:46

55

178.2

XLON

00378653993TRLO0.1.1

16/11/2023

12:53:12

253

177.6

XLON

00378657008TRLO0.1.1

16/11/2023

13:04:18

229

177.6

XLON

00378658168TRLO0.1.1

16/11/2023

13:14:46

822

177.6

XLON

00378659705TRLO0.1.1

16/11/2023

13:14:46

304

177.6

XLON

00378659704TRLO0.1.1

16/11/2023

13:14:47

445

178.4

CHIX

00378659715TRLO0.1.1

16/11/2023

13:23:22

68

178.4

CHIX

00378660803TRLO0.1.1

16/11/2023

13:23:22

559

178.4

CHIX

00378660804TRLO0.1.1

16/11/2023

14:13:01

44

181.4

CHIX

00378668034TRLO0.1.1

16/11/2023

14:15:00

738

181.4

CHIX

00378668283TRLO0.1.1

16/11/2023

14:15:00

290

181.4

CHIX

00378668282TRLO0.1.1

16/11/2023

14:16:51

62

180.6

AQXE

00378668555TRLO0.1.1

16/11/2023

14:16:51

44

180.6

AQXE

00378668556TRLO0.1.1

16/11/2023

14:16:51

1608

180.8

XLON

00378668557TRLO0.1.1

16/11/2023

14:16:53

83

180.6

AQXE

00378668560TRLO0.1.1

16/11/2023

14:30:06

1333

180

XLON

00378671318TRLO0.1.1

16/11/2023

14:30:06

275

180

XLON

00378671317TRLO0.1.1

16/11/2023

14:30:06

96

180

TRQX

00378671319TRLO0.1.1

16/11/2023

14:35:52

535

179.6

BATE

00378673323TRLO0.1.1

16/11/2023

14:35:52

189

179.6

AQXE

00378673322TRLO0.1.1

16/11/2023

14:35:54

469

179.6

BATE

00378673329TRLO0.1.1

16/11/2023

14:35:56

399

179.4

XLON

00378673341TRLO0.1.1

16/11/2023

14:35:58

230

179.4

XLON

00378673358TRLO0.1.1

16/11/2023

14:36:22

1515

179.4

XLON

00378673484TRLO0.1.1

16/11/2023

14:36:22

8

178.8

TRQX

00378673485TRLO0.1.1

16/11/2023

14:36:22

96

178.8

TRQX

00378673486TRLO0.1.1

16/11/2023

14:38:53

44

177

XLON

00378674986TRLO0.1.1

16/11/2023

14:38:59

1093

177

XLON

00378675043TRLO0.1.1

16/11/2023

14:38:59

1007

177

XLON

00378675044TRLO0.1.1

16/11/2023

15:18:11

39

178.8

AQXE

00378701571TRLO0.1.1

16/11/2023

15:19:35

150

178.8

AQXE

00378702453TRLO0.1.1

16/11/2023

15:26:20

555

178.8

CHIX

00378706657TRLO0.1.1

16/11/2023

15:37:44

359

178.8

XLON

00378711360TRLO0.1.1

16/11/2023

15:55:03

20

179

AQXE

00378717258TRLO0.1.1

16/11/2023

16:00:27

189

178

AQXE

00378718912TRLO0.1.1

16/11/2023

16:00:27

121

178

AQXE

00378718913TRLO0.1.1

16/11/2023

16:02:47

458

178.8

XLON

00378719557TRLO0.1.1

16/11/2023

16:14:20

421

178

BATE

00378725757TRLO0.1.1

16/11/2023

16:20:54

483

178

XLON

00378728660TRLO0.1.1

16/11/2023

16:21:08

536

178

CHIX

00378728773TRLO0.1.1

16/11/2023

16:21:08

362

178

XLON

00378728774TRLO0.1.1

16/11/2023

16:21:08

763

178

XLON

00378728775TRLO0.1.1

16/11/2023

16:21:09

96

177

TRQX

00378728785TRLO0.1.1

16/11/2023

16:21:09

189

176.8

AQXE

00378728801TRLO0.1.1

16/11/2023

16:21:09

522

178

BATE

00378728802TRLO0.1.1

16/11/2023

16:21:26

6

177.8

BATE

00378728983TRLO0.1.1

16/11/2023

16:22:22

83

177.6

BATE

00378729524TRLO0.1.1

16/11/2023

16:23:37

240

177.6

CHIX

00378730195TRLO0.1.1

16/11/2023

16:23:37

72

177.6

CHIX

00378730194TRLO0.1.1

16/11/2023

16:23:37

240

177.6

CHIX

00378730196TRLO0.1.1

16/11/2023

16:24:45

266

177.6

CHIX

00378730962TRLO0.1.1

16/11/2023

16:24:45

240

177.6

CHIX

00378730963TRLO0.1.1

16/11/2023

16:27:08

265

177.6

CHIX

00378732578TRLO0.1.1

16/11/2023

16:27:08

125

177.6

CHIX

00378732579TRLO0.1.1

16/11/2023

16:29:37

503

177.6

BATE

00378733908TRLO0.1.1

16/11/2023

16:29:37

37

177.6

BATE

00378733909TRLO0.1.1

16/11/2023

16:29:37

30

177.6

BATE

00378733910TRLO0.1.1

16/11/2023

16:29:40

24

177.6

BATE

00378734059TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFEALLLRLIV
12345678910
Date   Source Headline
4th Jun 20265:37 pmRNSHolding(s) in Company
29th May 20265:00 pmRNSHolding(s) in Company
27th May 20265:30 pmRNSHolding(s) in Company
22nd May 20265:00 pmRNSHolding(s) in Company
15th May 20267:00 amRNSCorrection - Holding(s) in Company
13th May 202612:00 pmRNS-RPRTC To Showcase Deupirfenidone at ATS Conference
8th May 20267:00 amRNSHolding(s) in Company
7th May 20266:27 pmRNSHolding(s) in Company
1st May 20267:00 amRNSPureTech's Seaport Prices Upsized IPO Nasdaq: SPTX
29th Apr 20267:01 amRNSFinal Results
29th Apr 20267:00 amRNSPRTC Voluntarily Delists Nasdaq Depositary Shares
27th Apr 20266:09 pmRNSHolding(s) in Company
27th Apr 202612:05 pmRNS-RPRTC's Seaport Adds Neuropsychiatry Veteran to BOD
24th Apr 20265:58 pmRNSHolding(s) in Company
22nd Apr 202612:00 pmRNS-RPRTC's Gallop: Positive Ph1 Topline MDS & AML Data
16th Apr 20265:00 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSHolding(s) in Company
13th Apr 20267:05 amRNSNotice of Results
13th Apr 20267:00 amRNSPRTC's Seaport Files for Proposed Nasdaq IPO
1st Apr 20267:00 amRNSTotal Voting Rights
25th Mar 20266:00 pmRNS-RPRTC’s Seaport: GlyphAllo Paper Published
13th Mar 20264:35 pmRNSPDMR Notification RSU Vesting
2nd Mar 20267:00 amRNSTotal Voting Rights
25th Feb 20267:00 amRNS-RPRTC to Present at Leerink Healthcare Conference
19th Feb 20265:15 pmRNS-RPRTC's Deupirfenidone Granted FDA & EU ODD for IPF
6th Jan 202612:00 pmRNS-RPureTech to Present at the JP Morgan Conference
18th Dec 20257:00 amRNSPureTech Appoints Robert Lyne as CEO
10th Dec 20255:41 pmRNSResults of AGM on June 16, 2025 – Update Statement
10th Dec 20255:30 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RPRTC: Successful FDA Meeting; IPF Phase 3 in 1H26
5th Dec 20256:00 pmRNS-RPRTC's Gallop: Positive Initial Topline AML Data
18th Nov 20255:30 pmRNSHolding(s) in Company
7th Nov 20256:18 pmRNSHolding(s) in Company
3rd Nov 20252:00 pmRNS-RPRTC: New LYT-200 AML Data + Update at ASH
22nd Oct 20257:00 amRNS-RPRTC: New IPF Data Show Benefit in Older Patients
17th Oct 20255:30 pmRNSHolding(s) in Company
14th Oct 20257:00 amRNSHolding(s) in Company
10th Oct 20255:59 pmRNSHolding(s) in Company
9th Oct 20256:10 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSHolding(s) in Company
29th Sep 20257:00 amRNS-RPRTC: New IPF Data Show Switch Patients Stabilized
24th Sep 20257:00 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Sep 20255:30 pmRNSHolding(s) in Company
19th Sep 20255:52 pmRNSHolding(s) in Company
19th Sep 20257:00 amRNSHolding(s) in Company
11th Sep 202512:05 pmRNS-RPRTC's Seaport Advances 2nd Candidate Into Clinic
4th Sep 20255:30 pmRNSHolding(s) in Company
1st Sep 20257:00 amRNSTotal Voting Rights
28th Aug 20257:00 amRNSHalf-year Report
21st Aug 202512:00 pmRNS-RPureTech Showcases Differentiated IPF Strategy
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
INTU
INTU.L
LSE
0.00%
IPE
IPE.L
LSE
0.00%
SKY
Sky
LSE
0.00%
DORE
Downing Renewa.
LSE
0.00%
APTD
Aptitude
LSE
-0.45%
Trending